Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15316825 | 0.95 | MCHR1 (0.47) | MCHR1CSF1RCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL14197570 | 0.86 | CSF1R (0.44) | CSF1RCYP2C19CYP2C9CYP3A4FGFR1 | |
| SCHEMBL19302326 | 0.85 | CSF1R (0.58) | CSF1RCYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL15316821 | 0.84 | CSF1R (0.55) | CSF1RCYP2C19CYP2C9CYP3A4FGFR1 | |
| SCHEMBL15316826 | 0.81 | LTA4H (0.42) | CSF1RCYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL21304793 | 0.80 | CSF1R (0.59) | CSF1RCYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL15316822 | 0.79 | CYP3A4 (0.44) | CSF1RCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL15316820 | 0.78 | CYP2C19 (0.44) | CSF1RCYP2C19CYP2C9CYP3A4FGFR1 | |
| SCHEMBL15316818 | 0.78 | CYP3A4 (0.55) | CSF1RCYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL15316819 | 0.78 | CYP2C19 (0.44) | CSF1RCYP2C19CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9730918-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9550768-B2 | Kinase modulation and indications therefor | PLEXXIKON INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160243092-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2016-08-25 | — | — | US | disclosed |
| US-9358235-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2014-08-28 | — | — | US | disclosed |
| US-8722702-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140037617-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130178473-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8461169-B2 | Compounds modulating c-fms and/or c-kit activity | PLEXXIKON INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8404700-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110166174-A1 | COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037617-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | MCHR1 4091/4885CSF1R 147/4885CYP2C19 3521/4885 |
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | FLT3, MET, BTK | MCHR1 4473/4885CSF1R 33/4885CYP2C19 4477/4885 |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MCHR1 1824/4885CSF1R 4/4885CYP2C19 3327/4885 |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MCHR1 1824/4885CSF1R 4/4885CYP2C19 3327/4885 |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MCHR1 1824/4885CSF1R 4/4885CYP2C19 3327/4885 |
| US-20160243092-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | MCHR1 4091/4885CSF1R 147/4885CYP2C19 3521/4885 |
| US-20110166174-A1 | COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MCHR1 2218/4885CSF1R 7/4885CYP2C19 3012/4885 |
| US-20130178473-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MCHR1 1824/4885CSF1R 4/4885CYP2C19 3327/4885 |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | MCHR1 4091/4885CSF1R 147/4885CYP2C19 3521/4885 |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | KIT, FLT3, FER | MCHR1 1997/4885CSF1R 10/4885CYP2C19 3400/4885 |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MCHR1 1824/4885CSF1R 4/4885CYP2C19 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.